BIOMED 101 + aldesleukin

**BIOMED 101 + aldesleukin** is a combination therapy, composed of BIOMED 101 (details on BIOMED 101 are not available in the provided sources) and **aldesleukin** (a recombinant form of human interleukin-2, known commercially as Proleukin). Aldesleukin is a biologic cytokine therapy that acts as an immunomodulator, stimulating the proliferation and activation of T-cells, B-cells, natural killer cells, and other immune effector cells. Its primary mechanism is to bind to high-affinity interleukin-2 receptors, resulting in a cytokine cascade and activation of cytotoxic lymphocytes. Aldesleukin is approved for metastatic renal cell carcinoma and has been studied and utilized widely in metastatic melanoma, either as monotherapy or as a component in multi-agent regimens. The efficacy of aldesleukin in combination regimens for melanoma is documented, with up to 56% response rates in chemoimmunotherapy settings, though these do not always translate to increased survival[1][2][3]. The toxicity profile is significant, including capillary leak syndrome and cardiovascular effects[3]. There is no substantial information about BIOMED 101 from the search results provided; as such, the mechanism and indication of the "BIOMED 101" component are unknown.

Brand names

Proleukin

Other names

recombinant interleukin-2IL-2IL2IL 2